LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent.
about
The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 MelanomaNegative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapyThe oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilizationThe oncolytic peptide LTX-315 triggers immunogenic cell death.The oncolytic peptide LTX-315 triggers necrotic cell death.The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells.LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment.Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications.Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model.Dermaseptin-PH: A Novel Peptide with Antimicrobial and Anticancer Activities from the Skin Secretion of the South American Orange-Legged Leaf Frog, Pithecopus (Phyllomedusa) hypochondrialis.Effects of talactoferrin alpha on lung adenoma prevention in A/J mice June 2, 2016.The oncolytic compound LTX-401 targets the Golgi apparatus.Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animalsThe anticancer peptide RT53 induces immunogenic cell death
P2860
Q35924903-30EE31AF-EAEA-457E-9932-3EF2A3FCBD7AQ36356176-A4910AA8-B417-49E2-B793-AF8567DB52E0Q36413553-459AB00C-5681-44BE-B3A3-AE2647994C7FQ36774984-D02D63F1-F26E-47DC-A13D-61C47BBFA746Q36780793-8AE28BBC-5082-49C6-9ED5-46D9DC2CDEFAQ37181696-2C1CFC8B-AFBB-4ABF-890E-8595884A2A8FQ38260167-A01D9E6E-57D1-4063-8248-06EE71B9AF43Q38685556-F7A67D67-59D9-4357-B6AC-CD6621E00417Q39250554-91F765F3-4A2A-4270-85B2-61E51148ADCEQ41338711-43778486-E953-46AD-A682-F4E9547F41A7Q48137993-C256CC86-7230-4BBF-ABCE-0EB5A0519410Q52720148-926499EA-7746-443B-B3BD-5179373A3929Q53035836-34670BDA-B191-4509-8DB3-0226AB8F87FEQ57796314-80BA4626-46A2-4BFA-A4F1-DB0D12D4B2AFQ58799814-CEB1793F-E310-45EB-A438-346FAB8310BE
P2860
LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
LTX-315 (Oncopore™): A short s ...... novel immunotherapeutic agent.
@en
LTX-315
@nl
type
label
LTX-315 (Oncopore™): A short s ...... novel immunotherapeutic agent.
@en
LTX-315
@nl
prefLabel
LTX-315 (Oncopore™): A short s ...... novel immunotherapeutic agent.
@en
LTX-315
@nl
P2093
P2860
P356
P1433
P1476
LTX-315 (Oncopore™): A short s ...... novel immunotherapeutic agent.
@en
P2093
Baldur Sveinbjörnsson
Ketil André Camilio
Oystein Rekdal
P2860
P304
P356
10.4161/ONCI.29181
P577
2014-06-25T00:00:00Z